Education
About Us
Working with TipRanks
Follow Us
Citius Oncology, Inc. (CTOR)
NASDAQ:CTOR
CTOR Stock Chart & Stats
$1.07
-$0.06(-4.78%)
At close: 4:00 PM EST
$1.07
-$0.06(-4.78%)
Day’s Range― - ―
52-Week Range$0.59 - $6.19
Previous CloseN/A
Volume120.49K
Average Volume (3M)329.57K
Market Cap
$56.77M
Enterprise Value$53.27M
Total Cash (Recent Filing)$7.30M
Total Debt (Recent Filing)$3.80M
Price to Earnings (P/E)―
Beta0.80
Next Earnings
May 20, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding88,275,210
10 Day Avg. Volume259,720
30 Day Avg. Volume329,575
Financial Highlights & Ratios
PEG Ratio-0.45
Price to Book (P/B)3.32
Price to Sales (P/S)0.00
P/FCF Ratio-27.08
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue13.51
Enterprise Value/Gross Profit16.89
Enterprise Value/Ebitda-2.45
Forecast
1Y Price Target
$6.00Price Target Upside460.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.14
Revenue Forecast (FY)$38.87M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy In Difficult TumorsAnalyst highlights objective responses and clinical benefit for Lymphir in a difficult-to-treat gynecologic cancer cohort where checkpoint monotherapies typically show low response rates, indicating potential to expand beyond niche indications.
Reimbursement And Commercial ReadinessAnalyst points to assignment of a permanent J-code along with established commercial manufacturing capacity and distribution partnerships as factors that enable reimbursement access and reliable product supply for early market uptake.
Safety ProfileAnalyst notes that Phase 1 combination of Lymphir with a checkpoint inhibitor was generally well tolerated, with no unexpected safety signals or serious immune-related adverse events, supporting broader combination use.
Bears Say
Clinical And Execution RiskAnalyst warns that current evidence is limited, which raises clinical and execution risk for the investment thesis and could delay program advancement or wider adoption.
Data Maturity RiskAnalyst cautions that reported results derive from early-stage top-line data and require confirmation in larger, more detailed studies, creating significant uncertainty around clinical outcomes.
Equity DilutionAnalyst notes recent equity financing materially increased shares outstanding and issued warrants, producing dilution that offsets some valuation gains from the drug launch.
Citius Oncology News
CTOR FAQ
What was Citius Oncology, Inc.’s price range in the past 12 months?
Citius Oncology, Inc. lowest stock price was $0.59 and its highest was $6.19 in the past 12 months.
What is Citius Oncology, Inc.’s market cap?
Citius Oncology, Inc.’s market cap is $56.77M.
When is Citius Oncology, Inc.’s upcoming earnings report date?
Citius Oncology, Inc.’s upcoming earnings report date is May 20, 2026 which is in 59 days.
How were Citius Oncology, Inc.’s earnings last quarter?
Citius Oncology, Inc. released its earnings results on Feb 13, 2026. The company reported -$0.06 earnings per share for the quarter, missing the consensus estimate of -$0.04 by -$0.02.
Is Citius Oncology, Inc. overvalued?
According to Wall Street analysts Citius Oncology, Inc.’s price is currently Undervalued.
Does Citius Oncology, Inc. pay dividends?
Citius Oncology, Inc. does not currently pay dividends.
What is Citius Oncology, Inc.’s EPS estimate?
Citius Oncology, Inc.’s EPS estimate is -0.01.
How many shares outstanding does Citius Oncology, Inc. have?
Citius Oncology, Inc. has 88,275,210 shares outstanding.
What happened to Citius Oncology, Inc.’s price movement after its last earnings report?
Citius Oncology, Inc. reported an EPS of -$0.06 in its last earnings report, missing expectations of -$0.04. Following the earnings report the stock price went up 3.39%.
Which hedge fund is a major shareholder of Citius Oncology, Inc.?
Currently, no hedge funds are holding shares in CTOR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Citius Oncology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (460.75% Upside)
$6.00 (460.75% Upside)
Blogger Sentiment
Bullish
CTOR Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
5.40%
12-Months-Change
Fundamentals
Return on Equity
-55.19%
Trailing 12-Months
Asset Growth
21.54%
Trailing 12-Months
Company Description
Citius Oncology, Inc.
Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.
CTOR Stock 12 Month Forecast
Average Price Target
$6.00
▲(460.75% Upside)
Technical Analysis
Ownership Overview
6.93% Insiders
0.29% Mutual Funds
6.46% Other Institutional Investors
85.69% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---